Dr. Patrick Couvreur is Full Professor of Pharmacy at the Paris-Sud University and holder of the chair of “Innovation Technologique” (2009-2010) at the prestigious « Collège de France ». He is appointed as a Senior Member of the “Institut Universitaire de France” since 2009. He is also the recipient of an “ERC Advanced Grant” (2010-2015) and of an “ERC Proof of Concept” (2015-2016). He has hold many important national and international academic positions as Director of the UMR CNRS 8612 (a CNRS associated departement gathering together more than 120 researchers in the drug delivery field), Director of the Doctoral School “Therapeutic Innovation” (over 300 PhD students at Paris-Sud University), founder member of the pole of competitivity MEDICEN, Extraordinary Professor at the University of Louvain (Belgium), member of the board of governors of many international scientific organizations (ie. The International Pharmaceutical Federation FIP, the Controlled Release Society CRS, the European Federation of Pharmaceutical Scientists, APGI etc.).
Prof Patrick Couvreur’s contributions in the field of drug delivery, nanomedicine and drug targeting are highly recognized around the world with more than 500 peer review research publications (Google Scholar H-index 118 and Thomson Reuters H-index 86), some of them in prestigious journals (Nature Nanotechnology, Nature Materials, Nature Communications, Proceedings of the National Academy of Sciences, Angewandte Chemie, Cancer Research, Journal of American Chemical Society etc.). His research is interdisciplinary, aiming at developping new nanomedicines for the treatment of severe diseases. This research is at the interface between Physico-Chemistry of Colloids, Polymer Chemistry, Material Science, Cellular and Molecular Biology and Experimental Pharmacology.
Patrick Couvreur’s research has led to the funding of two start-up companies (Bioalliance and Medsqual). Bioalliance (now ONXEO) entered the stock market in 2005 and a nanomedicine invented in Couvreur’s lab is currently finishing phase III clinical trial for the treatment of the hepatocarcinoma.
The major scientific contribution of Patrick Couvreur to the Pharmaceutical Sciences is also recognized by numerous international (the “2004 Pharmaceutical Sciences World Congress Award”, the prestigious “Host Madsen Medal”, the “European Pharmaceutical Scientist Award” of the European Federation of Pharmaceutical Sciences, the European Inventor Award 2013 given by the European Patent Office and the Higuchi Award 2015, Japan) and national awards (the “Prix Galien 2009” and the “Médaille de l’Innovation 2012 of the CNRS). His appointment as a member of eight academies (Académie des Sciences, Académie des Technologies, Académie Nationale de Médecine and Académie Nationale de Pharmacie in France, as well as the Académie Royale de Médecine in Belgium, the Royal Academy of Pharmacy in Spain, the United States National Academy of Medicine and the United States National Academy of Engineering) is another recognition of major scientific and scholarly contributions of Patrick Couvreur.